Highlights Argenica Therapeutics Limited

Equities

AGN

AU0000150328

Market Closed - Australian S.E. Other stock markets 07:10:37 17/05/2024 BST			5-day change	1st Jan Change
0.67 ^AUD	-0.74%		+8.94%	+31.37%

05-15	Argenica Therapeutics' Neuroprotective Drug ARG-007 Shows Positive Results in Ferret Preclinical Study	MT
04-16	Euroz Hartleys Adjusts Argenica Therapeutics’ Price Target to AU$1.40 From AU$1.50, Keeps at Speculative Buy	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Argenica Therapeutics' Neuroprotective Drug ARG-007 Shows Positive Results in Ferret Preclinical Study	05-14	MT
Argenica Therapeutics Raises AU$12 Million via Placement	04-12	MT
Argenica Therapeutics Doses First Batch of Patients for Phase Two Stroke Trial	04-10	MT
Argenica Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-27	CI
Argenica Therapeutics Secures AU$2 Million R&D Tax Rebate for Fiscal Year 2023	11-13	MT
Argenica Therapeutics Secures Ethics Approval for Phase 2 Stroke Trial	12/09/23	MT
Argenica Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	22/08/23	CI
Argenica Therapeutics Files Ethics Application for Phase Two Stroke Trial	19/07/23	MT
Argenica Therapeutics Limited Releases Safety Data for its Phase 1 Clinical Trial of ARG-007 in Healthy Human Volunteers	05/03/23	CI
Argenica Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	27/02/23	CI
Argenica Therapeutics Secures Grant Funding to Advance Development of Alzheimer’s Disease Medication	22/02/23	MT
Argenica Therapeutics Limited Announces Preclinical Data Shows ARG-007 Inhibits A Cause of Alzheimers	08/02/23	CI
Argenica Therapeutics Secures AU$1.2 Million Grant Funding for Brain Injury Treatment; Shares Up 6%	20/01/23	MT
Argenica Therapeutics Limited Announces Successful Completion of Phase 1 Clinical Trial Dosing	20/12/22	CI
Argenica Therapeutics Limited Approves Commencement of Fourth and Final Cohort Dosing	07/12/22	CI
Argenica Therapeutics Limited Announces That the First Subjects in the Third Cohort of Its Phase 1 Clinical Trial of ARG-007 Have Been Dosed	24/11/22	CI
Argenica Therapeutics Limited Announces the Approval by the Phase 1 Safety Review Committee to Progress to the Third Escalated Dose Cohort	17/11/22	CI
Argenica Therapeutics Limited Announces Sentinel Subjects Dosed in Second Cohort of Phase 1 Trial	06/11/22	CI
Argenica Therapeutics Limited Announces the Approval by the Phase 1 Safety Review Committee to Progress to the Second Escalated Dose Cohort	01/11/22	CI
Argenica Therapeutics Limited Announces Healthy Participants in the First Cohort of Its Phase 1 Clinical Trial of ARG-007 Have Been Successfully Dosed, Indicating Good Safety and Tolerability of ARG-007 in These Participants	25/10/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Argenica Therapeutics Limited

Equities

AGN

AU0000150328

Highlights

Filters